Gsa Capital Partners LLP X4 Pharmaceuticals, Inc Transaction History
Gsa Capital Partners LLP
- $1.32 Billion
- Q3 2024
A detailed history of Gsa Capital Partners LLP transactions in X4 Pharmaceuticals, Inc stock. As of the latest transaction made, Gsa Capital Partners LLP holds 507,694 shares of XFOR stock, worth $309,693. This represents 0.03% of its overall portfolio holdings.
Number of Shares
507,694Holding current value
$309,693% of portfolio
0.03%Shares
4 transactions
Others Institutions Holding XFOR
# of Institutions
103Shares Held
99.9MCall Options Held
213KPut Options Held
50.6K-
Bain Capital Life Sciences Investors, LLC Boston, MA16.9MShares$10.3 Million2.03% of portfolio
-
Nea Management Company, LLC Timonium, MD15MShares$9.14 Million0.77% of portfolio
-
Black Rock Inc. New York, NY10.7MShares$6.51 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.44MShares$5.15 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA7.13MShares$4.35 Million0.11% of portfolio
About X4 Pharmaceuticals, Inc
- Ticker XFOR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,646,096
- Market Cap $41.9M
- Description
- X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase...